Cytokinetics has filed a patent for novel tetrahydroisoquinoline derivative compounds that can be used as an active ingredient in pharmaceutical compositions. These compounds can be used to prevent or treat various diseases or conditions related to the contractility of skeletal sarcomere, such as neuromuscular disorders, voluntary muscle disorders, CNS disorders, muscle symptoms from systemic disorders, and dysfunctions of pelvic floor and urethral/anal sphincter muscle. The patent also claims a method for treating cachexia syndrome or muscle wasting caused by heart failure, cancer, chronic kidney disease, or dialysis by administering the compound. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cachexia syndrome or muscle wasting caused by various conditions
A recently filed patent (Publication Number: US20230125280A1) describes a method for treating cachexia syndrome or muscle wasting caused by heart failure, cancer, chronic kidney disease, or dialysis. The method involves administering a compound of the formula (I) or a salt thereof to a subject. The compound can have various substituents and configurations, as described in the claims.
The claims specify the structure and substituents of the compound, allowing for different variations. The compound can have different alkyl groups, alkyl groups substituted with various substituents, cycloalkyl groups, phenyl groups, heteroaryl groups, and more. The claims also describe the interaction of certain groups to form specific ring structures.
The patent claims also provide a list of specific compounds that can be used in the method. These compounds include (-)-2-(difluoromethyl)-8-ethyl-8-(2-hydroxyethyl)-6H-spiro[1,6-naphthyridine-5,3'-oxetan]-7(8H)-one, 4,4-diethyl-1,1-dimethyl-3-oxo-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, 8,8-diethyl-5,5-dimethyl-7-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-2-carbonitrile, and more. These compounds can be used in their salt forms as well.
The method described in the patent claims can be used to treat cachexia syndrome or muscle wasting caused by heart failure, cancer, chronic kidney disease, or dialysis. Cachexia syndrome is a condition characterized by severe weight loss and muscle wasting, often seen in patients with chronic illnesses. By administering the compound of formula (I) or its salts, the method aims to alleviate the symptoms of cachexia syndrome and muscle wasting.
In summary, the filed patent describes a method for treating cachexia syndrome or muscle wasting caused by various conditions. The method involves administering a compound of the formula (I) or its salts, which can have different substituents and configurations. The patent claims also provide a list of specific compounds that can be used in the method. This method has the potential to address the significant health challenges associated with cachexia syndrome and muscle wasting.
To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
